Latest Breaking News On - Pharmaceuticals nasdaq - Page 2 : vimarsana.com

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesPaula raganHead of corporate patient affairsEuropean medicines agencyExchange commissionAmerican society of hematologyClinical immunology societyDrug administrationDevelopment rd expensesPharmaceuticals reports firstPharmaceuticals nasdaqCompany contactReports first quarterProvides corporateChief executive officerRare pediatric disease priority review voucher

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesPharmaceuticals incHead of corporate patient affairsPharmaceuticals nasdaqCompensation committee of the board directorsCompany contactEquity incentive planNasdaq listing rule

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 01, 2024 (GLOBE NEWSWIRE) X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases o.

United statesCompensation committee of the board directorsHead of corporate patient affairsCompany contactPharmaceuticals incPharmaceuticals nasdaqEquity incentive planNasdaq listing rule

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01.05.2024 - BOSTON, May 01, 2024 (GLOBE NEWSWIRE) - X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on April 30, 2024, the company issued inducement .

United statesCompensation committee of the board directorsPharmaceuticals incPharmaceuticals nasdaqEquity incentive planNasdaq listing rule

ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for

SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today

United statesSan diegoEmma thompsonAshleyr robinsonFerda cevikbasSpurwing communicationsAmerican thoracic society international conferencePharmaceuticals nasdaqBronchial airway constrictionLifesci advisorsChronic obstructive pulmonary diseaseThoracic society international conferenceEblasakimab significantly alleviatesDerived lung slicesTranslational scienceSan mateo